Next, we designed and optimized antisense oligonucleotides (ASOs) to block these ESEs, and then, we significantly increased exon 3 skipping and reduced the expression of the functional, full-length PD-L1 on the surface of tumor cells as well as unexpected anti-proliferation and pro-pyroptosis effects in tumor cells. The gene discussed is CD274; the disease is neoplasm.